Staburo biostatistics support in diabetes trial
Another publication with Staburo biostatistics support, this time in diabetes type 2.
Background: Studies of dipeptidyl peptidase (DPP)-4 inhibitors report heterogeneous effects on endothelial function in patients with type 2 diabetes (T2D). This study assessed the effects of the DPP-4 inhibitor linagliptin versus the sulphonylurea glimepiride and placebo on measures of macro- and microvascular endothelial function in patients with T2D who represented a primary cardiovascular disease prevention population.
The full publication can be found here: https://cardiab.biomedcentral.com/articles/10.1186/s12933-016-0493-3
Enjoy reading!
Feel free to reach out to us if you need support in your study!
Staburo delivered biostatistics services in this bioavailability study.
The Staburo SAS programming environment facilitates the creation of meaningful outputs, such as tables, listings and figures (TLFs), from client supplied data.
We wish all our partners and future partners, all our employees and future employees, and all their families a wonderful Christmas and a great start in 2017. Staburo will continue to support you with experienced biostatisticians and statistical programmers next year and in the years to come!
This talk provided insight into the system of the AMNOG and the hurdles which have to be overcome in the assessment of a benefit, with focus on the statistical needs. In particular, the process at the German authorities “Gemeinsamer Bundesausschuss” (G-BA) and “Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen” (IQWiG) should be outlined.
This year’s Staburo Christmas party took place in the Barschule München, where we learned very much about famous Cocktails, its variants and how to produce them.
Recent Comments